Joint fluid alpha defensin nucleic acid aptamer and detection product thereof

By developing the joint fluid α defensive nucleic acid aptamer S9-60, combined with fluorophores and quenching chains, the complex and time-consuming problem of joint fluid α defensive detection is solved, and efficient and accurate diagnosis of peripheral infection of joint prosthesis is achieved. , significantly better than traditional methods.

CN118979041APending Publication Date: 2024-11-19FIRST HOSPITAL AFFILIATED TO GENERAL HOSPITAL OF PLA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411138817.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The existing joint fluid α defensin detection methods have the problems of complex detection process, long time and low accuracy, especially when diagnosing infections around joint prosthesis, it is difficult to accurately judge.

Method used

A joint fluid alpha defensin nucleic acid aptamer was developed. The S9-60 aptamer obtained by screening the nucleotide sequence, combining fluorophores and quenching chains, was used to prepare a diagnostic kit to achieve quantitative detection of joint fluid. α defense, optimized detection methods to improve sensitivity and specificity.

Benefits of technology

A high-affinity, fast and economical quantitative detection of articular fluid α defensin is achieved, and the AUC, sensitivity and specificity are significantly better than traditional protein antibody methods, shortening the detection time and cost.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118979041A_ABST
    Figure CN118979041A_ABST
Patent Text Reader

Abstract

The invention discloses a synovial fluid alpha defensin nucleic acid aptamer and a detection product thereof. The nucleotide sequence of the nucleic acid aptamer is as shown in SEQ ID NO: 6 or a single-stranded DNA molecule with the same specific recognition function is obtained by performing nucleotide deletion, increase or replacement on the basis of the sequence. The nucleic acid aptamer can be used for preparing a product for diagnosing infection around a joint prosthesis, and has the advantages of high affinity, high sensitivity, strong specificity, low detection time cost, low economic cost and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of molecular biology technology, and in particular to a synovial fluid α-defensin nucleic acid aptamer and a detection product thereof. Background Art

[0002] Clinical diagnosis of periprosthetic joint infections (PJI) is mainly based on the patient's local joint symptoms and clinical manifestations. However, periprosthetic joint infections often manifest as low-toxic infections, and it is not reliable to diagnose periprosthetic joint infections based solely on symptoms. Furthermore, the positive rate of microbial culture of low-toxic infections is not high, and serological inflammatory indicators are easily affected by systemic diseases.

[0003] Due to the above limitations, more and more scholars are committed to finding new biomarkers of synovial fluid, among which α-defensin is the most concerned by clinicians. There is evidence that in patients with periprosthetic joint infection, regardless of the virulence of the pathogen, α-defensin will be released into the synovial fluid. The currently commonly used quantitative detection of α-defensin is through ELISA method. The disadvantage is that the sample needs to be sent to the laboratory for testing, and the detection process is complicated and time-consuming. There are also commercial test strips that can qualitatively detect α-defensin. Although it is easy to use, the accuracy of α-defensin detection is significantly reduced, which ultimately affects clinical judgment. Summary of the invention

[0004] In order to solve the above technical problems, the present invention provides a synovial fluid α-defensin nucleic acid aptamer, the nucleotide sequence of the nucleic acid aptamer is shown in SEQ ID NO:6.

[0005] Specifically, the synovial fluid α-defensin nucleic acid aptamer can also be a single-stranded DNA molecule obtained by deleting, adding or replacing nucleotides from the aforementioned nucleic acid aptamer and having the same specific recognition function as the nucleic acid aptamer with the nucleotide sequence shown in SEQ ID NO:6.

[0006] Preferably, the synovial fluid α-defensin nucleic acid aptamer is obtained by deleting nucleotides from the aforementioned nucleic acid aptamer, and its nucleotide sequence is shown in SEQ ID NO:7.

[0007] Furthermore, the nucleotide sequence of the nucleic acid aptamer is coupled with a fluorescent group, a quenching group, biotin, a nanomaterial, a thiol group, an amino group or an enzyme.

[0008] The present invention also provides a use of the aforementioned joint fluid α-defensin nucleic acid aptamer in the preparation of a product for diagnosing periarticular infection of a joint prosthesis.

[0009] Specifically, the present invention provides a kit for diagnosing periprosthetic joint infection, wherein the kit comprises the aforementioned synovial fluid α-defensin nucleic acid aptamer.

[0010] Furthermore, the kit also includes a quenching chain, which is a nucleic acid fragment that is complementary to the nucleotide sequence of the synovial fluid α-defensin nucleic acid aptamer.

[0011] Furthermore, the nucleotide sequence of the quenching strand is shown in SEQ ID NO: 5. The kit also includes PBS + Mg containing 1 mg / mL BSA. 2+ Buffer and α-defensin standard, the buffer is used to dissolve the α-defensin standard, the PBS+Mg 2+ The buffer contains 1 mM Mg 2+ The kit also includes 1 mM Mg 2+ PBS solution, the 1 mM Mg 2+ The PBS solution is used to prepare the aptamer-quenching chain incubation system solution and dissolve the sample to be tested.

[0012] The beneficial effects of the present invention include:

[0013] 1. The nucleic acid aptamer S9-60 obtained by the present invention has a high affinity for α-defensin, with a KD value of 0.928 μM. -7 The order of magnitude is comparable to that of protein antibodies (the KD value of protein antibodies is generally around 10 -6 -10 -9 S9-60 can be used as a nucleic acid aptamer for quantitative detection of α-defensins in synovial fluid. Its chemical properties determine that it is superior to the currently used protein antibodies in terms of thermal stability, economy, and batch-to-batch consistency.

[0014] 2. In the test of measuring α-defensins in joint samples for PJI diagnosis, the method of quantitatively detecting α-defensins in joint fluid using the aptamer S9-60 of the present invention had an AUC, sensitivity, and specificity of 0.882, 90.6%, and 80.9%, respectively, which was superior to the commercial kit using protein antibodies (manufacturer R&D, AUC, sensitivity, and specificity were 0.763, 73.4%, and 70.8%, respectively).

[0015] 3. The method of quantitatively detecting α-defensins in synovial fluid using the aptamer S9-60 of the present invention is significantly superior to the commercial kit (R&D) using protein antibodies in terms of both time cost and economic cost: the two take approximately 75 to 90 minutes and 20 to 22 hours, respectively; the measurement cost per sample is approximately 7 to 15 CNY and 120 to 160 CNY, respectively. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 This is a schematic diagram of the α-defensin Capture-SELEX technology route;

[0017] Figure 2 Schematic diagram of gel elution method;

[0018] Figure 3 Schematic diagram of competitive quenching method;

[0019] Figure 4 The affinity of 5thR22S9 to different concentrations of α-defensin was verified by gel elution method; "↑" indicates the incubation supernatant, and "↓" indicates the remaining library eluted from the agarose sphere with 98% formamide solution containing 10 mM EDTA;

[0020] Figure 5 The secondary structure diagrams of aptamer 5thR22S9 and optimized aptamer S9-60;

[0021] Figure 6 The competitive quenching method was used to verify the affinity of aptamers 5thR22S9 and S9-60 for α-defensin; A is the fluorescence intensity change law in different solvents after the two aptamers were mixed with the quenching chain in different proportions, and B is the fluorescence change law in different solvents after the two aptamers were paired with the quenching chain at a ratio of 1:3 and different concentration gradients of α-defensin were added;

[0022] Figure 7 The results of intra-day and inter-day fluorescence value determination of S9-60 method. DETAILED DESCRIPTION

[0023] The present invention is further illustrated and described below in conjunction with embodiments, but the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. Based on the present invention and embodiments, all other inventions and embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0024] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0025] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0026] Example 1: Screening of synovial fluid α-defensin targeting nucleic acid aptamers

[0027] The specific steps are as follows:

[0028] S1. Synthesis of random nucleic acid aptamer library and related primers

[0029] The sequence of the random aptamer library is 5'-GGAGG CTCTC GGGAC GAC-(N30)-GT CGTCC CGATGCTGCA ATCGT AA-3' (SEQ ID NO: 1, N represents any base among A, T, G, and C); the forward primer (SEQ ID NO: 2) is 5'-FAM-GGAGG CTCTC GGGAC GAC-3' (the subsequent secondary libraries are therefore all labeled with FAM); the reverse primer (SEQ ID NO: 3) is 5'-Biotin-TTACG ATTGC AGCAT CGGGA CG-3'; the capture chain (Capture chain, SEQ ID NO: 4) labeled with biotin is 5'-GTC GTCCC GAGAG CCATA-Biotin-3' (complementary to the 5' end of the library).

[0030] S2. Screening: Using recombinant human α-defensin as the target substance, such as Figure 1 As shown, the Capture-SELEX technology route was used to screen aptamers specific for α-defensins. The specific steps are as follows:

[0031] ① Library-Capture chain complementary pairing: Prepare PBS containing 1mM MgCl2 (denoted as PBS+Mg 2+ ). 2+ The dissolved library and capture chain were mixed at a 1:5 molar ratio, incubated at 95°C for 5 min and at room temperature for ≥30 min to complete complementary pairing.

[0032] ②Immobilization: Streptavidin-labeled agarose beads (referred to as sugar beads; GE, USA) were used as the immobilization medium; they were injected into a 200 μL pipette tip with a small filter plugged at the distal end to make a sugar bead column, and PBS+Mg 2+ Wash 3 times. Pass the paired products in step ① through the column, and the library is hung on the sugar ball with the help of the capture chain.

[0033] ③ Incubation: a. Reverse: Use PBS + Mg containing 1 mg / mL BSA 2+ (Counter-selected substances) Rinse the sugar column and discard the effluent to improve the specificity of the aptamer. b. Forward: Use ddH2O to dissolve α-defensin, and the concentration decreases in rounds (5μM to 0.8μM in rounds); rinse the sugar column with α-defensin solution and collect the effluent.

[0034] ④Enrichment: The effluent obtained in step ③ was subjected to polymerase chain reaction (PCR). The PCR amplification system contained 1.2μM forward primer, 1.2μM reverse primer, 75μM deoxyribonucleoside triphosphate (dNTP), 0.025U / μL Taq DNA polymerase, and ultrapure water was used to make up the volume. 1×PCR Buffer was used as the system solvent (all reagents involved were produced by TaKaRa, Japan). The PCR reaction amplification conditions were: a. Pre-denaturation: 95℃, 120s; b. 10 to 15 cycles as follows: 1) Denaturation: 95℃, 30s, 2) Annealing: 60℃, 30s, 3) Extension: 72℃, 30s; c. Renaturation: 72℃, 120s. d. Storage: 4℃.

[0035] ⑤ Single-stranded: PCR product (double-stranded) passes through a newly prepared sugar ball column, and the secondary library is hung on the column by the biotin of the reverse primer-antisense strand. Use 1mM NaOH to rinse the sugar ball column, the double strands are unwound, and the secondary library flows out with the outflow. Use a 3K ultrafiltration tube for concentration.

[0036] The random aptamer library of the first round was replaced by the secondary library, and steps ①-⑤ were repeated for a total of 22 rounds.

[0037] S3. Characterization: Adopt Figure 2 The gel elution method shown was used to verify the affinity of the secondary libraries in each round and the secondary library of the final round product.

[0038] Gel elution method: ① 400 pmol of each round of secondary library or screened aptamer is paired with the capture chain at a ratio of 1:5. ② Pass the mixture in ① through a sugar column. ③ Transfer the sugar column to an Eppendorf tube, discard the supernatant, and add PBS+Mg 2+ The solution forms a suspension, which is fixed to 130 μL and divided into 20 μL×6 portions. ④ The concentration of α-defensin is titrated at 50 μL / portion, and each portion is added to the Ep tube described in ③ and incubated at room temperature for 30 minutes. Take 40 μL of the supernatant for later use. ⑤ Add 50 μL of 98% formamide solution containing 10 mM ethylenediaminetetraacetic acid (EDTA) to the remaining sugar ball solution, and heat at 95°C for 10 minutes to release the remaining library or aptamer fixed on the sugar ball. Collect the released supernatant, about 60 μL per portion. ⑥ The liquid collected in ④ and ⑤ is subjected to 15% polyacrylamide gel electrophoresis (PAGE), 150V, 30min. ⑦ Scan the gel for fluorescence, and the elution amount of the library or aptamer can be inferred by the fluorescence intensity reflected by the grayscale of the image, so as to compare the affinity.

[0039] The gel elution fluorescence scanning of the final round product (5thR22S9) is shown in Figure 4 As shown in Figure 2, gel elution is used as a preliminary verification method for aptamer binding. Its interpretation mainly relies on observing the overall gradient changes of the bands, such as Figure 4 As shown, the overall band intensity is positively correlated with the system concentration of the target, so 5thR22S9 was finally confirmed to be the nucleic acid aptamer of α-defensin, and its sequence obtained by sequencing was 5'-GGAGG CTCTC GGGAC GACAC AAAGC TGCGC GCACT ATCCG TCAGG CGTGTCGTCC CGATG CTGCA ATCGT AA-3' (SEQ ID NO: 6).

[0040] S4. Optimization and standard verification: Optimize 5thR22S9 to further improve the affinity between the aptamer and the target substance, remove the free ends in the secondary structure (such as Figure 5 The obtained new aptamer was named S9-60, and the sequence was: 5'-AGGCT CTCGG GACGA CACAA AGCTG CGCGC ACTAT CCGTC AGGCG TGTCG TCCCG ATGCT-3' (SEQ ID NO: 7). S9-60 was firstly subjected to gel elution to confirm that its affinity was positive. Figure 3 Competitive quenching method (PBS + Mg containing 1 mg / mL BSA) 2+ as solvent), and the affinity of 5thR22S9 or S9-60 was verified using a quenching chain (BHQ-1_18bp, SEQ ID NO: 5) with a sequence of 5'-GTCGT CCCGA GAGCC ATA-BHQ-1-3' (nt sequence was the same as the Capture chain).

[0041] Competitive quenching method: The biotin group of the capture chain is modified into a fluorescent quenching group (i.e. Quencher-cDNA), and when it is complementary to the library / aptamer labeled with the fluorescent group, the fluorescence is (reversibly) quenched; after the complementation is completed, α-defensin is added to the system, which competes with the quenching chain through the configuration change of the library / aptamer, so that the fluorescence reappears. The fluorescence intensity result can be used for both qualitative characterization and inference of the KD value (see the principle). Figure 3 ), but the result depends on the normal reading of fluorescence. Figure 6 As shown in B, only PBS+Mg containing 1 mg / mL BSA was used. 2+ Only when the reaction system is used as a solvent can fluorescence appear normally (possible reason: protein-peptide will have a masking effect on fluorescence, but the effect has a platform, so BSA is added to the reaction system to mask the influence of α-defensin on fluorescence).

[0042] Specifically, PBS+Mg 2+ (Contains 1mM Mg 2+ PBS solution) and BSA (PBS+Mg containing 1 mg / mL BSA 2 + ) was used as solvent to verify the quenching effect of BHQ-1_18bp on 5thR22S9 and S9-60. The results are as follows Figure 6 As shown in A.

[0043] The concentration gradient of α-defensin was established, and then the competitive quenching method was performed using BHQ-1_18bp as Quencher-cDNA (the concentration was 3 times that of the aptamer). 5thR22S9, S9-60 and PBS+Mg 2+ (PBS solution containing 1mM Mg2+), BSA (PBS+Mg2+ containing 1mg / mL BSA 2+ ) The two solvents were combined in pairs to verify the affinity of 5thR22S9 or S9-60 with AD-1. The results are as follows Figure 6 As shown in B. Figure 6 B shows that compared with the system with BSA as solvent, the 2+ In the system with BSA as solvent, the binding and dissociation between the aptamer and Quencher-cDNA (BHQ-1_18bp) could not be carried out or could not be reflected in the fluorescence intensity; while in the system with BSA as solvent, the affinity of S9-60 was better than that of 5thR22S9. And according to the fitting results, the KD of S9-60 = KD1 / KD2 = 15.941μM / 17.180 = 0.928μM (10 -7 orders of magnitude, comparable to protein antibodies).

[0044] Example 2: Method for quantitative detection of α-defensins in synovial fluid based on aptamer S9-60 (referred to as S9-60 method) and its stability evaluation

[0045] (1) Human recombinant α-defensin-1 (human recombinant AD-1) was used as a standard. The standard was dissolved in PBS + Mg containing 1 mg / mL BSA. 2+ The standard solutions were dissolved in PBS and diluted in gradient to obtain concentrations of 2 μM, 1 μM, 0.5 μM, 0.25 μM, ... 0, respectively, and added to the corresponding wells of the ELISA plate, with an addition volume of 25 μL per well; the aptamer S9-60 (synthesized by Shanghai Biotech, with the fluorescent group FAM coupled to the 5' end of the SEQ ID NO: 7 sequence) and the quenching chain were added in PBS + Mg 2+The aptamer-quencher chain incubation system solution was prepared to a final concentration of 100 nM:300 nM, and the aptamer-quencher chain incubation system solution was mixed with the standard solution at 25 μl / well and incubated for 20 min to 30 min. Then, the fluorescence values ​​were quickly read at Ex490 nm and Em 525 nm using an ELISA reader to draw a standard curve.

[0046] (2) The sample to be tested was washed with PBS + Mg 2+ After diluting once (to avoid the sample being too viscous, which will affect the mixing of the reaction system and fluorescence reading, etc.), add it to the corresponding wells of the ELISA plate, with an addition volume of 25 μL per well. Mix the aptamer-quencher chain incubation system solution with the sample to be tested at 25 μL / well and incubate for 20 to 30 minutes, then quickly use an ELISA reader to read the fluorescence value at Ex490nm and Em 525nm.

[0047] (3) The fluorescence value of the synovial fluid sample to be tested is compared with the standard curve to achieve quantitative detection of the α-defensins contained therein.

[0048] The stability of this method is tested by the coefficient of variation CV value. The CV value is a common indicator for methodological stability assessment and daily quality control in clinical laboratory diagnostics. The relevant items can be found in the industry standards for methodological establishment or inspection line acceptance. In this case, CV is used to evaluate the stability of the S9-60 method, and the threshold value refers to the clinical inspection industry standard for D-dimer (Health Industry Standard of the People's Republic of China WS / T 477-2015) (intra-day CV value <0.10, inter-day CV value <0.15).

[0049] The fluorescence value was measured at wavelength Ex: 490nm, Em: 525nm, and the first measurement on the first day was recorded as "1-1", the second measurement on the first day was recorded as "1-2", and so on. Among them, in the three measurements of 1-1, 1-2, and 1-3, the concentration values ​​of the standard were set to 0.5μM, 0.25μM, 0.125μM, 0.0625μM, 0.03125μM, and 0μM; in the six measurements of 2-1, 2-2, 2-3, 3-1, 3-2, and 3-3, the concentration values ​​of the standard were set to 1μM, 0.5μM, 0.25μM, 0.125μM, 0.0625μM, 0.03125μM, and 0μM. The fluorescence value measurements are as follows: Figure 7As shown. 0.5μM and 0.0625μM were randomly selected to calculate the CV values. At 0.5μM, the intra-day CV values ​​were 0.058, 0.066, and 0.091, respectively, and the average intra-day CV value was 0.072; the average inter-day CV value was 0.118. At 0.0625μM, the intra-day CV values ​​were 0.012, 0.039, and 0.117, respectively, and the average intra-day CV value was 0.091; the average inter-day CV value was 0.127. It can be seen from the above data that the average intra-day CV value and the average inter-day CV value are both within their corresponding threshold ranges, indicating that the S9-60 method has a high stability.

[0050] Example 3: Analysis of the sensitivity and specificity of the clinical application of aptamer S9-60 in diagnosing PJI

[0051] The S9-60 method and ELISA method (R&D brand finished kit, commonly used in foreign clinical practice) were used to detect 153 joint fluid samples, and the 2014 MSIS diagnostic standard was used as the diagnostic standard for PJI. The AUC of the aptamer S9-60 method for diagnosing PJI was 0.882, 95%CI (0.826, 0.939), sensitivity = 90.6%, specificity = 80.9%, PPV = 77.3%, NPV = 92.3%; the AUC of the ELISA method for diagnosing PJI was 0.763, 95%CI (0.686, 0.840), sensitivity = 73.4%, specificity = 70.8%, PPV = 64.4%, NPV = 78.8%.

[0052] Obviously, the various diagnostic performance indicators of the aptamer S9-60 of the present invention are better than those of the ELISA method, and the detection time is greatly shortened (1 hour vs. 1 day).

Claims

1. A synovial fluid α-defensin nucleic acid aptamer, characterized in that: The nucleotide sequence of the nucleic acid aptamer is shown in SEQ ID NO:

6.

2. A joint fluid α-defensin nucleic acid aptamer, characterized in that: A single-stranded DNA molecule having the same specific recognition function as the nucleic acid aptamer according to claim 1, obtained by deleting, adding or replacing nucleotides from the nucleic acid aptamer according to claim 1.

3. The synovial fluid α-defensin nucleic acid aptamer according to claim 2, characterized in that The nucleotide sequence of the nucleic acid aptamer according to claim 1 obtained by deleting nucleotides is shown in SEQ ID NO:

7.

4. The synovial fluid α-defensin nucleic acid aptamer according to any one of claims 1 to 3, characterized in that The nucleotide sequence of the nucleic acid aptamer is coupled with a fluorescent group, a quenching group, biotin, a nano material, a sulfhydryl group, an amino group or an enzyme.

5. Use of the synovial fluid α-defensin nucleic acid aptamer according to any one of claims 1 to 4 in the preparation of a product for diagnosing periprosthetic joint infection.

6. A kit for diagnosing periprosthetic joint infection, characterized in that: The kit comprises the synovial fluid α-defensin nucleic acid aptamer according to any one of claims 1 to 4.

7. The kit according to claim 6, characterized in that The kit also includes a quenching chain, which is a nucleic acid fragment that is complementary to the nucleotide sequence base of the synovial fluid α-defensin nucleic acid aptamer.

8. The kit according to claim 7, characterized in that The nucleotide sequence of the quencher strand is shown in SEQ ID NO:

5.

9. The kit according to claim 7, characterized in that The kit also includes PBS + Mg containing 1 mg / mL BSA 2+ Buffer and α-defensin standard, the buffer is used to dissolve the α-defensin standard, the PBS+Mg 2+ The buffer contains 1 mM Mg 2+ of PBS solution.

10. The kit according to claim 7, characterized in that The kit also includes 1 mM Mg 2+ PBS solution, the 1 mM Mg 2+ The PBS solution is used to prepare the aptamer-quenching chain incubation system solution and dissolve the sample to be tested.